CD19 and neoplasm: CD20-TCB can be efficiently combined with the bispecific antibody fusion protein CD19-4-1BBL, that provides co-stimulatory signals to tumor-engaged immune cells (T cells or NK cells) and this combination immunotherapy has been shown to promote intratumoral TILs accumulation and increased anti-tumor efficacy in preclinical models of NHL (282).